��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2001, 27(3) 144-147 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	5-֬��ø��Ƽ�
	LTA₄ˮ��ø��Ƽ�
	LTB₄��׿��
	��
	��
	֣��У
	PubMed
	Article by ��
	Article by ֣��У

5-֬��ø;��м��

��¹, ֣��У²

1. �й�ҽѧ��ѧԺƤ��о��;
2. �й�Э��ҽ�ƴ�ѧƤ��о��

ժҪ��

�ع˻��ϩ��5-֬��ø��л;��м��е��Լ�5-֬��ø��Ƽ��ϩA4ˮ��ø��Ƽ��Ͱ��ϩB4�׿��м��Ч��ĿǰΪֹ,û��һ��5-֬��ø��Ƽ��ܳɹ��м��,��ϩA4ˮ��ø��Ƽ��Ͱ��ϩB4�׿��ȱ��ٴ�ǰ��ٴ��ϡ�

�ؼ���� м�� 5-֬��ø��Ƽ� LTA₄ˮ��ø��Ƽ� LTB₄��׿��

1. �й�ҽѧ��ѧԺƤ��о��;
2. �й�Э��ҽ�ƴ�ѧƤ��о��

Abstract:

Keywords:

�ո�� �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Steinhilber D.5-Lipoxygenase:a target for antiinflammatory drugs revisited.Curr Med Chem,1999,6(1):71-85.
[2] Feltenmark S,Runarsson G,Larsson P,et al.Diverse expression of cytosolic phospholipase A₂,5-lipoxygenase and prostaglandin H synthase 2 in acute pre-B-lymphocytic leukaemia cells.Br J Haematol,1995,90(3):585-594.
[3] Stankova J,Rola-Pleszczynski M,Dubois CM.Granulocytemacrophage colony-stimulating factor increases 5-lipoxygenase gene transcription and protein expression in human neutrophils.Blood,1995,85(12):3719-3726.
[4] Iversen L,Deleuran B,Hoberg AM,et al.LTA₄ hydrolase in human skin:decreased activity,but normal concentration in lesional psoriatic skin evidence for different LTA₄ hydrolase activity in human lymphocytes and human skin.Arch Dermatol Res,1996,288:217-224.
[5] Iversen L,Kragballe K,Ziboh VA.Significance of leukotriene-A₄ hydrolase in the pathogenesis of psoriasis.Skin Pharmacol,1997,10(4):169-177.
[6] Iversen L,Kristensen P,Nissen JB,et al.Purification and characterization of leukotriene A4 hydrolase from human epidermis.FEBS Lett,1995,358(3):316-322.
[7] van de Kerkhof PC,van Pelt H,Lucker GP,et al.Topical R85355,a potent and selective 5-lipoxygenase inhibitor fails to improve psoriasis.Skin Pharmacol,1996,9(5):307-311.
[8] Degreef H,Dockx P,De Doncker P,et al.A double-blind vehicle-controlled study of R 68151 in psoriasis:a topical 5-lipoxygenase inhibitor.J Am Acad Dermatol,1990,22(5 Pt 1):751-755.
[9] Metzman M,Hogan D.Topical 5-lipoxygenase inhibitors in the treatment of psoriasis.J Dermatol Treat,1991,2:117-120.
[10] Ford-Hutchinson AW.5-lipoxygenase activation in psoriasis:a dead issue? Skin Pharmacol,1993,6(4):292-297.
[11] Yuan JH,Birkmerier J,Yang DC,et al.Isolation and identification of metabolites of leukotriene A4 hydrolase inhibitor SC57461 in rats.Drug Metab Dispos,1996,24(10):1124-1133.
[12] Tsuji F,Miyake Y,Enomoto H,et al.Effect of SA6541,a leukotriene a4 hydrolase inhibitor,and indomethacin on carragenan-induced murine dermatitis.Eur J Pharmacol,1998,346(1):81-85.
[13] Penning TD,Chandrakumar NS,Chen BB,et al.Structure-activity relationship studies on 1-[ 2-(4-Phenylphenoxy) ethyl] pyrrolidine(SC-22716),a potent inhibitor of leukotriene A(4)(LTA(4)) hydrolase.J Med Chem,2000,43(4):721-735.
[14] Iverson L,Svendsen M,Kragballe K.Cyclosporin a downreglates the LTA₄ hydrolase level in human keratinocyte cultures.Acta Dermatol Venereol,1996,76:424-428.
[15] Zhu YI,Stiller MJ.Preview of potential therapeutic applications of lerkotriene B4 inhibitors in dermatology.Skin Pharmacol Appl Skin Physiol,2000,13:235-245.
[16] Spanbroek R,Stark HJ,Janssen-Timmen U,et al.5-lipoxygenase expression in langerhans cells of normal human epidermis.Proc Natl Acad Sci USA,1998,95:663-668.